Document is current
Any future updates will be listed below
-
Authors
Xiao, Muran
Kondo, Shinji
Nomura, Masaki
Kato, Shinichiro
Nishimura, Koutarou
Zang, Weijia
Zhang, Yifan
Akashi, Tomohiro
Viny, Aaron https://orcid.org/0000-0001-7039-0110
Shigehiro, Tsukasa https://orcid.org/0000-0002-5286-5108
Ikawa, Tomokatsu
Yamazaki, Hiromi
Fukumoto, Miki
Tanaka, Atsushi https://orcid.org/0000-0002-9449-4894
Hayashi, Yasutaka
Koike, Yui
Aoyama, Yumi
Ito, Hiromi
Nishikawa, Hiroyoshi
Kitamura, Toshio https://orcid.org/0000-0001-7855-1767
Kanai, Akinori
Yokoyama, Akihiko https://orcid.org/0000-0002-5639-8068
Fujiwara, Tohru
Goyama, Susumu https://orcid.org/0000-0002-9339-1826
Noguchi, Hideki
Lee, Stanley C. https://orcid.org/0000-0001-7110-2416
Toyoda, Atsushi https://orcid.org/0000-0002-0728-7548
Hinohara, Kunihiko
Abdel-Wahab, Omar https://orcid.org/0000-0002-3907-6171
Inoue, Daichi https://orcid.org/0000-0002-7947-6540
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (21ck0106697h0001)
MEXT | Japan Society for the Promotion of Science (JP20H00537)
MEXT | Japan Society for the Promotion of Science (JP20H03717)
MEXT | Japan Society for the Promotion of Science (16H06279)
- License Information
-
More Information
Article History
Received: 28 July 2022
Accepted: 29 November 2023
First Online: 15 December 2023
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, and Janssen, Loxo Oncology/Lilly and is on the Scientific Advisory Board of Envisagenics Inc and Harmonic Discovery Inc.; O.A.-W. has received prior research funding from H3B Biomedicine, Loxo Oncology/Lilly, Minovia Therapeutics, and Nurix Therapeutics unrelated to the current manuscript. D.I. has received prior research funding from Abbvie and Sumitomo Dainippon Pharma unrelated to the current manuscript. The remaining authors declare no competing interests.
